Zoetis Inc.
ZTS · NYSE
- $72.97
- $30.44B
- Open
- —
- —
- $73.49 - $74.82
- $71.00 - $150.05
- —
- —
- 3.77M
About Zoetis Inc.
Zoetis is an animal-health company that develops and sells medicines and related products for animals. Its business spans companion-animal products and livestock-oriented animal health, with operations in the United States and internationally; the supplied earnings coverage identifies companion-animal products and international growth as key areas of focus. It makes money primarily through product sales to veterinary and animal-care channels. Zoetis reported fiscal 2025 revenue of $9.5 billion and net income of $2.7 billion, compared with $9.3 billion and $2.5 billion, respectively, in fiscal 2024. The supplied evidence does not quantify revenue by segment.
Notable Price Movement
- Aug 3-7$72.665.99%
The stock fell $1.47, or 1.90%, from $77.51 to $76.04 over the supplied period. It initially edged up to $77.93 on July 29, then gave back that gain with a $1.90 drop on July 30, recovered to $77.29 on July 31, and slipped from $77.10 on August 3 to $76.04 on August 4. No company-specific announcement is supplied as a direct catalyst. Instead, the available Zoetis coverage centers on the approaching second-quarter report, with companion-animal products and international growth providing potential support while U.S. competition and concerns about Librela weigh on sentiment. The evidence does not identify a broader market driver, so the decline appears to have occurred without a disclosed weekly catalyst.
